Back

BET inhibition in cardiovascular disease: a new dawn?

28 August 2016 (13:25 - 13:40)
Organised by:
Congress Presentation Part of: A novel approach for high CV risk patients with diabetes: the potential of epigenetics Primary cardiovascular prevention: interventions and outcomes ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor John Kastelein

Academic Medical Centre, Amsterdam (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Introduction - A novel approach for high CV risk patients with diabetes: the potential of epigenetics.
Professor S. Del Prato (Pisa, IT)
Presentation thumbnail
The high risk diabetes patient with cardiovascular disease: what else can we target to reduce cardiovascular risk?
Professor K. Ray (London, GB)
Presentation thumbnail
Understanding BET inhibition as a novel pathway for cardiovascular risk modulation.
Doctor J. Plutzky (Boston, US)
Presentation thumbnail
Discussion & summary - A novel approach for high CV risk patients with diabetes: the potential of epigenetics.
Professor S. Del Prato (Pisa, IT) Professor K. Ray (London, GB)

Access the full session

Session thumbnail
A novel approach for high CV risk patients with diabetes: the potential of epigenetics

The Event

Event poster

ESC Congress 2016

28 August 2016 13:25 CET
You may be interested in
thumbnail
Congress Presentation
The BET protein inhibitor apabetalone (RVX-208) prevents doxorubicin-induced endothelial senescence
31 August 2024
thumbnail
Congress Presentation
Novel multidisciplinary cardiometabolic clinic in a UK tertiary cardiology centre: early activity, interventions and potential for cardiovascular risk optimisation
27 August 2021
thumbnail
Congress Presentation
Atherosclerotic cardiovascular events associated with BTK inhibitors: a systematic review and meta-analysis of harms
20 June 2025
thumbnail
Congress Session
Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources